C14H22N2O.HCl
C14H23ClN2O
|
InChI=1S/C14H22N2O.ClH/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4;/h7-9H,5-6,10H2,1-4H3,(H,15,17);1H |
IYBQHJMYDGVZRY-UHFFFAOYSA-N |
[Cl-].CC[NH+](CC)CC(=O)Nc1c(C)cccc1C |
|
local anaesthetic
Any member of a group of drugs that reversibly inhibit the propagation of signals along nerves. Wide variations in potency, stability, toxicity, water-solubility and duration of action determine the route used for administration, e.g. topical, intravenous, epidural or spinal block.
anti-arrhythmia drug
A drug used for the treatment or prevention of cardiac arrhythmias. Anti-arrhythmia drugs may affect the polarisation-repolarisation phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres.
|
|
View more via ChEBI Ontology
N-(2,6-dimethylphenyl)-N2,N2-diethylglycinamide hydrochloride
|
2-Diethylamino-2',6'-acetoxylidide hydrochloride
|
ChemIDplus
|
alpha-Diethylamino-2,6-acetoxylidine hydrochloride
|
ChemIDplus
|
Lidocaine hydrochloride anhydrous
|
ChemIDplus
|
omega-Diethylamino-2,6-dimethylacetanilide hydrochloride
|
ChemIDplus
|
Alphacaine N
|
DrugBank
|
Alphacaine SP
|
DrugBank
|
Anestacon
|
DrugBank
|
Esracaine
|
DrugBank
|
Lidocaton
|
ChEBI
|
Lidopen
|
ChEBI
|
3917968
|
Beilstein Registry Number
|
Beilstein
|
73-78-9
|
CAS Registry Number
|
ChemIDplus
|
|